In a report released on January 9, Roanna Ruiz from Leerink Partners maintained a Buy rating on Lantheus (LNTH – Research Report). The company’s shares closed yesterday at $59.29.
Ruiz covers the Healthcare sector, focusing on stocks such as Lantheus, Cytokinetics, and Vir Biotechnology. According to TipRanks, Ruiz has an average return of -16.1% and a 30.84% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Lantheus with a $98.75 average price target.
See the top stocks recommended by analysts >>
Based on Lantheus’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $319.95 million and a net profit of $131.96 million. In comparison, last year the company earned a revenue of $223.72 million and had a net profit of $43.06 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Lantheus (LNTH) Company Description:
Lantheus Holdings, Inc. engages in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, sonographers and technologists working in a variety of clinical settings. The firm operates through the following geographical segments: U.S. and International. The U.S. segment produces and markets medical imaging agents and products throughout the U.S. This segment sells its products to radio pharmacies, integrated delivery networks, hospitals, clinics and group practices. The International segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. The company was founded in 1956 and is headquartered in North Billerica, MA.
Read More on LNTH:
- Perspective Therapeutics enters strategic agreements with Lantheus
- Lantheus expands radiopharmaceutical oncology pipeline via agreements
- Lantheus Expands Radiopharmaceutical Oncology Pipeline via Strategic Agreements with Perspective Therapeutics
- Lantheus Reports Preliminary Fiscal Year 2023 Revenue
- Lantheus sees 2023 revenue $1.295B-$1.297B, consensus $1.27B
